MAPT and Alzheimer disease: In pilot studies, we found that soluble synaptotoxic tau-containing AD brain extract inhibited LTP in a manner that was resistant to TOMA1, leaving open the possibility that the oTau preparation only partly models the complexity of AD brain soluble tau.